Development of the new diagnosis and the new therapy for rheumatoid arthritis by microRNA
Project/Area Number |
20591171
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
膠原病・アレルギー・感染症内科学
|
Research Institution | Kobe University |
Principal Investigator |
NAKAMACHI Yuji Kobe University, 医学部附属病院, 臨床検査技師 (80379429)
|
Co-Investigator(Kenkyū-buntansha) |
KAWANO Seiji 神戸大学, 医学部附属病院, 講師 (20351512)
KUMAGAI Shunichi 神戸大学, 大学院・医学研究科, 教授 (00153346)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | マイクロRNA / 関節リウマチ |
Research Abstract |
We investigated the possibility of microRNA as a useful diagnostic marker or therapeutic drug for the treatment of rheumatoid arthritis. We used the rat adjuvant-induced arthritis model. We found that microRNA expression profile was different between the arthritis rat and non-arthritis rat at joint tissues and in mononuclear cells. We treated the adjuvant-induced arthritis rat with miR-124 by injecting into right hind heel, and the arthritis of miR-124 injected rats subsided compared to that of control rats. These results suggested that microRNA could be useful as a new diagnostic and therapueutic tool for rheumatoid arthritis.
|
Report
(4 results)
Research Products
(16 results)
-
-
-
-
-
[Journal Article] DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation.2008
Author(s)
Syampurnawati M, Tatsumi E, Ardianto B, Takenokuchi M, Nakamachi Y, Kawano S, Kumagai S, Saigo K, Matsui T, Takahashi T, Nagai K, Gunadi, Nishio H, Yabe H, Kondo S, Hayashi Y.
-
Journal Title
Leuk Res. 32
Pages: 1141-1143
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-